COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02281058
Recruitment Status : Unknown
Verified August 2017 by Victor Huang, Brigham and Women's Hospital.
Recruitment status was:  Active, not recruiting
First Posted : November 2, 2014
Last Update Posted : August 9, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):
Victor Huang, Brigham and Women's Hospital

Brief Summary:
Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are performing a pilot study for the treatment of new onset or actively progressing vitiligo with abatacept to determine if weekly self-injections of medication lead to clinical improvement in vitiligo lesions.

Condition or disease Intervention/treatment Phase
Vitiligo Drug: Abatacept Phase 1

Detailed Description:
Abatacept has been shown to decrease T cell activity and reduce symptoms associated with rheumatoid arthritis. Similar pathways have been shown to be involved in vitiligo. Therefore, we are recruiting 10 adult patients with active vitiligo who meet specific inclusion and exclusion criteria to receive self-administered injections of abatacept weekly starting at week 0 and continuing until week 24. A 32 week follow-up visit will be performed to evaluate secondary endpoints as well. We will be monitoring patients to see if skin lesions of vitiligo stop spreading and start to repigment with continued treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Study Start Date : January 2015
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo
Drug Information available for: Abatacept

Arm Intervention/treatment
Experimental: intervention group
Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
Drug: Abatacept
self-injected subcutaneous biologic medication
Other Name: Orencia

Primary Outcome Measures :
  1. change in repigmentation with abatacept therapy as measured using the Vitiligo Area and Severity Index (VASI) score [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. clinical safety and rate of adverse events as measured by patient-reported side effects [ Time Frame: 32 weeks ]
  2. percentage repigmentation with abatacept therapy as measured using the physician's global assessment [ Time Frame: 24 weeks ]
  3. effect on disease-related quality of life as measured using the validated Vitiligo Quality of Life (VitiQOL) tool [ Time Frame: 32 weeks ]
  4. maintenance of repigmentation after stopping therapy [ Time Frame: 32 weeks ]
  5. initial time to repigmentation [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-pregnant individuals ages 18 and older with a diagnosis of actively progressive skin lesions of clinically diagnosed vitiligo covering at 5% or great body surface area (defined as development of new lesions or worsening of existing lesions within the past 6 months) not receiving immune suppressive treatment. Both subjects who have received at least one therapy in the past and subjects currently receiving treatment at the time of screening will be eligible providing they undergo a wash out period prior to starting the study (2 weeks for topical agents and systemic agents with short half lives, 1 month for phototherapy)
  • Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug in such a manner that the risk of pregnancy is minimized
  • WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent units of HCG) within 0 to 48 hours before the first dose of study drug
  • Women must not be breast-feeding
  • Sexually active fertile men must use effective birth control if their partners are WOCBP

Exclusion Criteria:

  • Pregnant or breastfeeding patients
  • Patients with segmental, acrofacial, or universal vitiligo
  • Patients with evidence of poliosis (white hairs) within the majority (>50%) of their vitiligo lesions
  • Patients currently on any other systemic biologic medication, current use of Abatacept, or any other systemic biologic medication within 2 months of study (or within 5 half-lives of last dose of drug)
  • Use of systemic immunosuppressive agent within 2 weeks prior to initiation of Abatacept
  • Use of potent topical steroids, topical tacrolimus or pimecrolimus within 2 weeks prior to initiation of Abatacept
  • Use of phototherapy within one month prior to initiation of Abatacept therapy
  • Patients with a history of chronic obstructive pulmonary disease
  • History of active Mycobacterium tuberculosis infection (any subspecies) Use of any investigational medication within 28 days prior to enrollment or 5 half-lives if known (whichever is longer)
  • Receiving concomitant immune modulating therapy (see concomitant medications, section 8.6). Subjects receiving such agents at screening may be eligible to enroll following a washout period of 2 weeks for topical agents and systemic agents with short half lives
  • Subjects who are impaired, incapacitated, or incapable of completing study-related assessments
  • Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to vitiligo and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study
  • Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ. Existing non-melanoma skin cell cancers should be removed, the lesion site healed, and residual cancer ruled out before administration of the study drug
  • Subjects who currently abuse drugs or alcohol
  • Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
  • Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed
  • Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication
  • Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis, or bronchiectasis)
  • Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be subjects with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks)
  • Subjects must not be positive for hepatitis B surface antigen
  • Subjects must not be positive for HIV
  • Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay
  • Subjects with any of the following laboratory values Hemoglobin < 8.5 g/dL WBC < 3000/mm3 (< 3 x 109/L) Platelets < 100,000/mm3 (< 3 x 109/L) Serum creatinine > 2 times the ULN Serum ALT or AST > 2 times the ULN
  • Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study
  • Allergies to any components of abatacept or its vehicle
  • Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose
  • Any concomitant biologic DMARD, such as anakinra
  • Prisoners or subjects who are involuntarily incarcerated
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02281058

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Bristol-Myers Squibb
Layout table for additonal information
Responsible Party: Victor Huang, Physician, Brigham and Women's Hospital Identifier: NCT02281058    
Other Study ID Numbers: 2014P000699
First Posted: November 2, 2014    Key Record Dates
Last Update Posted: August 9, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Pigmentation Disorders
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents